Method of treating inflammation in the joints of a body

Abstract

A process for treating inflammation in a joint whether heat, redness, pain, swelling and/or stiffness, and for increasing motion and increasing joint space and correcting mal-alignment, comprising the steps of dissolving a quantity of growth hormone (somatotropin), preferably in purified form, in a buffer solution, and injecting one time or multiple repeat times, a single dosage of the mixture of purified growth hormone and buffer solution into the joint of a body so as to initiate the treatment process.

What is claimed is:  
     
         1 . A method of correcting a malalignment in an arthritic joint of a body, such as a bow-legged deformity, comprising the injection of at least a single dosage of a growth hormone in a range of 0.025 milligrams to 0.249 milligrams per kilogram of patient body weight dissolved in a buffer solution.  
     
     
         2 . A method of increasing the space between the bone ends of a patient's joint comprising the injection of at least a single dosage of a growth hormone in a range of 0.025 milligrams to 0.249 milligrams per kilogram of patient body weight dissolved in a buffer solution.  
     
     
         3 . A method of smoothing the surface of the bone ends of a patient's joint comprising the injection of at least a single dosage of a growth hormone in a range of 0.025 milligrams to 0.249 milligrams per kilogram of patient body weight dissolved in a buffer solution.  
     
     
         4 . An anti-inflammatory composition comprising a purified growth hormone of between 0.025 milligrams to 0.249 milligrams per kilo of a patient's body weight dissolved in a buffer solution of between 1 to 10 milliliters.  
     
     
         5 . An anti-inflammatory composition as recited in  claim 4  further comprising a local anesthetic.  
     
     
         6 . An anti-inflammatory composition as recited in  claim 4  further comprising an anti-protease agent.  
     
     
         7 . An anti-inflammatory composition as recited in  claim 4  further comprising an anti-enzyme agent.  
     
     
         8 . An anti-inflammatory composition comprising a purified growth hormone of between 0.5 milligrams to 10.0 milligrams per milliliter of a buffer solution.  
     
     
         9 . An anti-inflammatory composition as recited in  claim 8  further comprising a local anesthetic.  
     
     
         10 . An anti-inflammatory composition as recited in  claim 8  further comprising an anti-protease agent.  
     
     
         11 . An anti-inflammatory composition as recited in  claim 8  further comprising an anti-enzyme agent.  
     
     
         12 . An analgesic composition comprising a purified growth hormone of between 0.025 milligrams to 0.249 milligrams per kilo of a patient's body weight dissolved in a buffer solution of between 1 to 10 milliliters.  
     
     
         13 . An analgesic composition as recited in  claim 12  further comprising a local anesthetic.  
     
     
         14 . An analgesic composition as recited in  claim 13  wherein said local anesthetic comprises Lidocain in an amount of generally between about 0.5 milliliter to 10 milliliters.  
     
     
         15 . An analgesic composition as recited in  claim 14  further comprising a local anesthetic agent.  
     
     
         16 . An analgesic composition as recited in  claim 14  further comprising an anti-protease agent.  
     
     
         17 . An analgesic composition as recited in  claim 14  further comprising an anti-enzyme agent.  
     
     
         18 . An analgesic composition as recited in  claim 12  further comprising an anti-protease agent.  
     
     
         19 . An analgesic composition as recited in  claim 12  further comprising an anti-enzyme agent.  
     
     
         20 . An analgesic composition comprising a purified growth hormone of between 0.5 milligrams to 10.0 milligrams per milliliter of a buffer solution.